Cronos Group (NASDAQ:CRON - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01), Zacks reports. Cronos Group had a negative net margin of 42.65% and a negative return on equity of 2.56%. The company had revenue of $30.53 million for the quarter, compared to the consensus estimate of $48.64 million.
Cronos Group Stock Performance
CRON stock traded down $0.08 during trading on Monday, reaching $1.97. 1,844,219 shares of the company were exchanged, compared to its average volume of 1,731,098. The company has a market cap of $753.59 million, a P/E ratio of -15.15, a PEG ratio of 1.74 and a beta of 0.97. Cronos Group has a 52-week low of $1.83 and a 52-week high of $3.14. The stock's 50 day moving average price is $1.97 and its 200 day moving average price is $2.08.
Cronos Group Company Profile
(
Get Free Report)
Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.
Read More
Before you consider Cronos Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cronos Group wasn't on the list.
While Cronos Group currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
